glp 1 agonist overdose IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target GLP-1 Medications for Weight Loss:

Introduction Obesity is a global health problem and increases the risk of developing type II diabetes mellitus (T2DM), cardiovascular disease, and dyslipidemia

Clinical practice

Disproportionality analysis A sequential approach was adopted to systematically address major confounders: (1) An exploratory disproportionality approach comparing GLP-1RAs with all other drugs reported in the FAERS database, using venlafaxine as the positive control and empagliflozin/orlistat as the negative control

J Med Plants Res (2013) 2:2469

Funding The author(s) declare that no financial support was received for the research and/or publication of this article